Answers are grounded in this paper and cite their sources.
Case report highlights the diagnostic complexity and therapeutic challenges of simultaneous plasma cell myeloma and acute myelomonocytic leukemia.
Introduction/Objective The co-existence of plasma cell myeloma/multiple myeloma (PCM/MM) and acute myelomonocytic leukemia (AMML) is rare and presents a significant diagnostic challenge, with important implications for therapeutic management. Plasma cell myeloma (PCM), a neoplasm of terminally differentiated B-cells, typically presents with clonal plasma cell proliferation and associated monoclonal protein production. In contrast, acute myelomonocytic leukemia (AMML), a subtype of acute myeloid leukemia (AML), arises from early myeloid progenitors and is characterized by prominent monocytic differentiation and aggressive clinical behavior. We report a rare and diagnostically complex case of synchronous IgH::CCND1-positive PCM and poor-risk AMML in an elderly patient. Methods/Case Report An 83-year-old man presented to the emergency department with a three-day history of flu-like symptoms. Initial laboratory investigations revealed marked leukocytosis, with a white blood cell count of 48.97 × 109/L, monocytosis (28.5%), anemia and thrombocytopenia. Bone marrow biopsy aspirate blast count is 22%, the blasts are negative for CD34. The marrow also contained 14% monocytes and evidence of myeloid maturation. Plasma cells accounted for approximately 50% of marrow cellularity. Immunohistochemistry and in situ hybridization confirmed kappa light chain restricted plasma cells that aberrantly express, CD56, Cyclin D1, and CD20. Serum protein electrophoresis detected IgG Kappa monoclonal protein. Targeted next-generation sequencing (NGS) identified mutations in CBL, PTPN11, RUNX1, and SRSF2, supporting a background myeloid neoplasm. Myeloma-specific cytogenetics revealed a CCND1:IGH. The patient was initiated on combination therapy with decitabine and venetoclax. Myeloma markers declined on therapy. Results NA Conclusion The simultaneous occurrence of distinct hematolymphoid neoplasms without prior exposure to cytotoxic therapy is extremely rare and presents considerable challenges in diagnosis and treatment. In this case, AMML appears to have developed either de novo or as a transformation from chronic myelomonocytic leukemia (CMML-2), as evidenced by the presence of somatic mutations commonly seen in CMML. From a treatment perspective, managing both AMML and plasma cell myeloma (PCM) requires a carefully tailored strategy that addresses the aggressive behavior of AMML.
No takes yet. Share an insight, caveat, or question.
Nwanguma et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: